{"id":49012,"date":"2026-04-30T11:35:08","date_gmt":"2026-04-30T11:35:08","guid":{"rendered":"https:\/\/quickassetsmarket.com\/index.php\/2026\/04\/30\/eli-lilly-stock-jumps-6-after-strong-earnings-and-raised-guidance\/"},"modified":"2026-04-30T11:35:08","modified_gmt":"2026-04-30T11:35:08","slug":"eli-lilly-stock-jumps-6-after-strong-earnings-and-raised-guidance","status":"publish","type":"post","link":"https:\/\/quickassetsmarket.com\/index.php\/2026\/04\/30\/eli-lilly-stock-jumps-6-after-strong-earnings-and-raised-guidance\/","title":{"rendered":"Eli Lilly stock jumps 6% after strong earnings and raised guidance"},"content":{"rendered":"
<\/div>\n

Eli Lilly reported stronger-than-expected first-quarter earnings and revenue on Thursday, driven by robust demand for its blockbuster weight-loss and diabetes drugs, prompting the company to raise its full-year guidance.<\/p>\n

The pharmaceutical giant now expects 2026 revenue to range between $82 billion and $85 billion, up from its earlier forecast of $80 billion to $83 billion. <\/p>\n

It also lifted its adjusted profit outlook, projecting full-year earnings between $35.50 and $37 per share, compared with a prior range of $33.50 to $35.<\/p>\n

The share price of the company was up by over 6% during premarket hours. <\/p>\n

Blockbuster drugs Zepbound, Mounjaro fuel growth<\/h2>\n

Demand for the company\u2019s flagship drugs, Zepbound and Mounjaro, continued to underpin its performance, even as pricing pressures persist in the US market.<\/p>\n

Mounjaro posted $8.66 billion in quarterly sales, marking a 125% increase from a year earlier and comfortably beating analyst expectations of $7.26 billion, according to StreetAccount.<\/p>\n

Zepbound, launched about three years ago, generated $4.16 billion in US revenue during the quarter, up 80% year over year. <\/p>\n

The figure also exceeded estimates of $4.04 billion, despite a decline in realised prices.<\/p>\n

The continued momentum of these therapies has helped Eli Lilly deliver a string of strong quarters, as rising prescription volumes offset lower pricing.<\/p>\n

Earnings and revenue beat expectations<\/h2>\n

The company reported adjusted earnings per share of $8.55, well ahead of analyst estimates of $6.66, according to LSEG data. <\/p>\n

Revenue came in at $19.80 billion, surpassing expectations of $17.62 billion and representing a 56% increase from the same period last year.<\/p>\n

US revenue rose 43% to $12.1 billion, driven by a 49% increase in volume, reflecting higher demand for Mounjaro and Zepbound. <\/p>\n

However, this was partially offset by lower realised prices for Zepbound and some other treatments.<\/p>\n

Net income for the quarter stood at $7.4 billion, or $8.26 per share, compared with $2.76 billion, or $3.06 per share, a year earlier.<\/p>\n

Focus shifts to new obesity pill launch<\/h2>\n

While injectable therapies remain the company\u2019s primary growth driver, attention is increasingly turning to its newly approved GLP-1 obesity pill, Foundayo, which launched in the second quarter and was not included in the latest results.<\/p>\n

The rollout is expected to feature prominently in discussions with investors, particularly as the drug enters a competitive market alongside Novo Nordisk\u2019s rival pill Wegovy, which had an earlier start in the US.<\/p>\n

Early data suggests a measured start. <\/p>\n

Leerink Partners analyst David Risinger last week said initial prescription trends for the pill have been \u201cmodest,\u201d highlighting the challenges of scaling new treatments in a competitive landscape.<\/p>\n

Long-term demand outlook remains strong<\/h2>\n

Despite near-term pricing pressures, Eli Lilly remains optimistic about the long-term growth trajectory of the GLP-1 category.<\/p>\n

The company expects to benefit from broader insurance coverage, including potential Medicare support for obesity treatments later this year, as well as continued global demand for its existing therapies.<\/p>\n

Chief Executive Dave Ricks has previously indicated that lower prices in the US could help expand access and drive higher prescription volumes. <\/p>\n

He also expects the number of patients using GLP-1 drugs globally to increase from about 20 million at the end of last year to 30 million by the end of 2026.<\/p>\n<\/p>\n

The post Eli Lilly stock jumps 6% after strong earnings and raised guidance<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly reported stronger-than-expected first-quarter earnings and revenue on Thursday, driven by robust demand for its blockbuster weight-loss and diabetes drugs, prompting the company to raise its full-year guidance. The pharmaceutical giant now expects 2026 revenue to range between $82 billion and $85 billion, up from its earlier forecast of $80 billion to $83 billion. <\/p>\n","protected":false},"author":1,"featured_media":49013,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":{"0":"post-49012","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"_links":{"self":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/49012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/comments?post=49012"}],"version-history":[{"count":0,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/49012\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media\/49013"}],"wp:attachment":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media?parent=49012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/categories?post=49012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/tags?post=49012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}